Elucid is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its groundbreaking product, ElucidVivo, is the first FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, & plaque composition to inform risk of event (heart attack or stroke) and personalized treatment selection.
ElucidVivo is in use by cardiologists, vascular surgeons, radiologists, and neurologists across the US and EU at health systems, clinics, and research institutes. ElucidVivo has applications for coronary, carotid, and peripheral arteries.
In addition, Elucid also offers quantifying imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigative therapeutic agents to vascular disease
Location: United States, Massachusetts, Boston
Member count: 201-500
Total raised: $8M
Founded date: 2009
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 10.05.2021 | Series A | $8M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 19.07.2021 | Elucid Pre... | Elucid Founder, Andrew Buckler... | - | - | aithority.... |
| 10.05.2021 | Daily fund... | Kin raised $63.9M; Vanta lande... | - | Kristin Ka... | vator.tv/n... |
| 10.05.2021 | Elucid Rai... | Elucid, a Boston, MA-based med... | USA | - | finsmes.co... |